drugset / Trial / NCT00234000
Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes
Phase 1
Terminated
1 enrolled
Jonsson Comprehensive Cancer Center
CTI BioPharma · collabCelgene Corporation · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Drugs used in chemotherapy, such as azacitidine and arsenic trioxide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of azacitidine when given together with arsenic trioxide and to see how well they work in treating patients with myelodysplastic syndromes.
Timeline
- Start
- 2007-02
- Primary completion
- 2009-02
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 25 mg/m2 | Subcutaneous |
| Subject | Azacitidine | Other / unclassified | 50 mg/m2 | Subcutaneous |
| Subject | Azacitidine | Other / unclassified | 75 mg/m2 | Subcutaneous |
| Subject | arsenic trioxide | Small molecule | 1 mg/ml | Intravenous |